Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BMNDF and 80,000+ other tickers.
See exactly how BMNDF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BMNDF and 80,000+ other tickers.
Biomind Labs Inc. operates as a biotechnology firm dedicated to advancing innovative pharmaceutical therapies and sophisticated nanotech drug delivery mechanisms, primarily addressing a range of psychiatric and neurological disorders. Among its leading pipeline assets, BMND01 is currently in Phase II clinical trials for treating depression. Another key candidate, BMND08, a derivative of 5-Methoxy-N,N-dimethyltryptamine, is also in Phase II trials, addressing depression and anxiety specifically in patients experiencing cognitive decline associated with Alzheimer's disease. The company's…
VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"), and the Common Shares will commence trading on the CSE at market open on August 11, 2026 under the symbol "BMND". In connection with the listing of the Common Shares on the CSE, the Company will be delisting its Common Shares from the Cboe Canada (the "Cboe") effective close of business on August 10, 2026.
A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage bio-pharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today welcomes the historic executive order signed by President Trump to accelerate research, regulatory pathways, and patient access to psychedelic treatments. This landmark policy shift marks a turning point in U.S. healthcare and drug policy, one that aligns directly with Biomind's long-term vision: to redefine how the world treats mental health and brain-related conditions.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, is pleased to announce that it intends to complete a non-brokered private placement of up to 28,000,000 units of the Company (the "Units") at a price of $0.09per Unit for gross proceeds of up to C$2,520,000 (the "Offering"). Each Unit will be comprised of one common share in the capital of the Company (each, a "Common Share") and one Common Share purchase warrant (each, a "Warrant").
BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today announced a major strategic advancement in the development of BMND08, transitioning the program into FDA-directed activities using the Company's newly engineered nano-formulation drug-delivery platform, designed to support commercial-stage clinical trials in neuropsychiatric and neurodegenerative disorders. Following a Phase 2 trial that established a new benchmark in neurology with a 100% response rate in Alzheimer's-related mood disorders, Biomind is now introducing a proprietary nano-delivery technology for BMND08, engineered to deliver superior dosing precision, safety, absorption, and commercial-grade manufacturing scalability.
TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked its cease trade order issued on April 4, 2025 (the "FFCTO") against the Company effective November 25, 2025. The Company was cease traded by the Commission for failure to file audited financial statements for the year ended December 31, 2024, corresponding management's discussion and analysis and officers' certificates, and the annual information form for the year ended December 31, 2024.